NASDAQ$ACLX
Arcellx Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Reported business highlights and financial results.
Arcellx reported a successful year with a strategic collaboration with Kite, progress in clinical trials, and scalable manufacturing setup. The company's cash position is $580 million, which will fund operations through BLA filing of CART-ddBCMA planned for the first half of 2025.
- Signed strategic collaboration with Kite to co-develop and co-commercialize late-stage clinical CART-ddBCMA in multiple myeloma.
- Presented continued robust long-term responses from CART-ddBCMA Phase 1 expansion trial in patients with relapsed or refractory multiple myeloma.
- Enrolled and dosed patients in pivotal iMMagine-1 clinical program for patients with rrMM.
- Initiated ACLX-002 for patients with AML/MDS.
Headline financials
Revenue & EPS history
Arcellx · Revenue · Quarterly
$4.95M
Forward guidance
Arcellx anticipates completing enrollment of iMMagine-1, initiating iMMagine-2 in earlier multiple myeloma lines, and presenting longer-term data from the Phase 1 expansion study of CART-ddBCMA. The company is also beginning commercial planning as it prepares for U.S. market entry.
Tailwinds
- Completing enrollment of iMMagine-1
- Initiating iMMagine-2 in earlier multiple myeloma lines
- Presenting longer-term data from Phase 1 expansion study of CART-ddBCMA
- Beginning commercial planning
- Preparing for U.S. market entry
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2022
+2.2%
Avg return
Earnings day
+0.1%
Avg return
5 days after
+24.9%
Avg return
30 days after
58%
11 / 19 earnings
Positive
+16.0%
Q2 2024
Best reaction
-4.8%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -0.2% | -0.1% | +0.2% | |
| Q3 2025 | -1.9% | +2.2% | -21.1% | |
| Q2 2025 | -0.9% | -0.2% | +2.1% | |
| Q1 2025 | -0.2% | +10.9% | +9.0% | |
| Q4 2024 | +2.0% | +1.2% | -19.9% | |
| Q3 2024 | +10.8% | +8.1% | -9.1% | |
| Q2 2024 | +16.0% | +19.1% | +40.0% | |
| Q1 2024 | -4.8% | -3.1% | -2.8% | |
| Q4 2023 | -2.7% | +0.4% | +2.9% | |
| Q3 2023 | +4.3% | +21.3% | +11.0% | |
| Q2 2023 | +6.7% | +3.3% | -0.7% | |
| Q1 2023 | +2.8% | -4.5% | -3.7% | |
| Q4 2022 | +0.9% | -2.9% | +41.1% | |
| Q3 2022 | -2.8% | -4.9% | +47.5% | |
| Q3 2021 | -2.8% | -4.9% | +47.5% | |
| Q2 2022 | +8.4% | -4.1% | +10.5% | |
| Q1 2022 | +0.2% | -15.5% | +174.8% | |
| Q1 2021 | +0.2% | -15.5% | +174.8% | |
| Q4 2021 | +5.9% | -8.7% | -30.2% | |
| Q4 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro